3-Month (Jul 2025):
- AFP 14 ng/mL, no recurrence on CT, LFTs normal.

9-Month (Dec 2025):
- AFP 28 ng/mL, 1.1 cm enhancing nodule in segment V.
- Plan: TACE (Jan 2026).

Prognosis: Good long-term outlook with recurrence control and ongoing antiviral therapy.
